Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis

Clicks: 387
ID: 113002
2018
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Discontinuation of bDMARDs leads to an increased risk of losing remission or LDA and radiographic progression, while tapering doses of bDMARDs does not increase the risk of relapse (LDA) or radiographic progression, even though there is an increased risk of losing remission.
Reference Key
s2018annalsrisk Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Henaux S;Ruyssen-Witrand A;Cantagrel A;Barnetche T;Fautrel B;Filippi N;Lukas C;Raffeiner B;Rossini M;Degboé Y;Constantin A;;
Journal annals of the rheumatic diseases
Year 2018
DOI
DOI not found
URL
https://www.pubmed.gov/29187350/
Keywords
systematic review meta-analysis National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome female male Withholding Treatment* risk factors radiography antirheumatic agents / therapeutic use* arthritis rheumatoid / drug therapy* disease progression pmid:29187350 doi:10.1136/annrheumdis-2017-212423 sophie henaux adeline ruyssen-witrand arnaud constantin rheumatoid / diagnostic imaging biological products / therapeutic use* maintenance chemotherapy

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.